EP0940470A3 - Protéine de fusion et sa utilisation pour la détection des anticorps liée au diabète mellitus insulinodépendant - Google Patents

Protéine de fusion et sa utilisation pour la détection des anticorps liée au diabète mellitus insulinodépendant Download PDF

Info

Publication number
EP0940470A3
EP0940470A3 EP98660149A EP98660149A EP0940470A3 EP 0940470 A3 EP0940470 A3 EP 0940470A3 EP 98660149 A EP98660149 A EP 98660149A EP 98660149 A EP98660149 A EP 98660149A EP 0940470 A3 EP0940470 A3 EP 0940470A3
Authority
EP
European Patent Office
Prior art keywords
fusion protein
insulin
diabetes mellitus
dependent diabetes
simultaneous detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98660149A
Other languages
German (de)
English (en)
Other versions
EP0940470A2 (fr
Inventor
Ari Hinkkanen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wallac Oy
Original Assignee
Wallac Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wallac Oy filed Critical Wallac Oy
Publication of EP0940470A2 publication Critical patent/EP0940470A2/fr
Publication of EP0940470A3 publication Critical patent/EP0940470A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
EP98660149A 1998-01-29 1998-12-29 Protéine de fusion et sa utilisation pour la détection des anticorps liée au diabète mellitus insulinodépendant Withdrawn EP0940470A3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/015,399 US6770460B1 (en) 1998-01-29 1998-01-29 Fusion protein and its use in an immunoassay for the simultaneous detection of autoantibodies related to insulin-dependent diabetes mellitus
US15399 1998-01-29

Publications (2)

Publication Number Publication Date
EP0940470A2 EP0940470A2 (fr) 1999-09-08
EP0940470A3 true EP0940470A3 (fr) 2002-08-28

Family

ID=21771182

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98660149A Withdrawn EP0940470A3 (fr) 1998-01-29 1998-12-29 Protéine de fusion et sa utilisation pour la détection des anticorps liée au diabète mellitus insulinodépendant

Country Status (2)

Country Link
US (1) US6770460B1 (fr)
EP (1) EP0940470A3 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982323B1 (en) 1997-12-23 2006-01-03 Alexion Pharmaceuticals, Inc. Chimeric proteins for diagnosis and treatment of diabetes
CA2318355A1 (fr) * 1997-12-23 1999-07-01 Alexion Pharmaceuticals, Inc. Proteines chimeres pour le traitement du diabete
IL132611A0 (en) * 1999-10-27 2001-03-19 Yeda Res & Dev Synthetic genes and polypeptides and pharmaceutical compositions comprising them
DE50114032D1 (de) * 2000-04-10 2008-07-31 Merk Und Kollegen Gmbh Lab Dr Fusionsprotein zur gleichzeitigen Erkennung von humanen Autoantikörpern
KR100418465B1 (ko) * 2001-01-15 2004-02-14 서동상 인슐린 의존성 당뇨병의 유전자 치료방법 및 그 치료용 조성물
DE10106295C1 (de) * 2001-02-02 2002-08-22 Gaifar German American Inst Fo Protein mit mehreren Antigen-Epitop-Sequenzen, welches immobilisiert ist
IL158316A0 (en) * 2001-04-10 2004-05-12 Univ Leland Stanford Junior Therapeutic and diagnostic uses of antibody specificity profiles
US7378455B2 (en) * 2005-06-30 2008-05-27 General Electric Company Molding composition and method, and molded article
CN103788199B (zh) * 2012-10-30 2016-04-13 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
JP6196989B2 (ja) * 2013-02-05 2017-09-13 シスメックス株式会社 １型糖尿病の早期診断マーカーであるｇａｄ抗体の高感度測定方法
CN104098684B (zh) * 2013-04-03 2016-03-23 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
CN111175518A (zh) * 2020-01-08 2020-05-19 杭州北角医学检验所有限公司 一种用于ⅰ型糖尿病联合抗体检测试剂盒及其制备方法
CN117417427B (zh) * 2023-09-11 2024-05-07 江苏省人民医院（南京医科大学第一附属医院） 一种检测内源性自体胰岛素介导的胰岛素抗体的试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032984A1 (fr) * 1996-03-06 1997-09-12 Zymogenetics, Inc. PROTEINE-TYROSINE PHOSPHATASE AUTO-ANTIGENE DE 37 kD DU DIABETE SUCRE
US5674692A (en) * 1991-09-06 1997-10-07 Baekkeskov; Steinunn Methods for diabetes susceptibility assessment in asymptomatic patients
WO1999032136A1 (fr) * 1997-12-23 1999-07-01 Alexion Pharmaceuticals, Inc. Proteines chimeres pour le traitement du diabete

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8703682L (sv) * 1987-09-24 1989-03-25 Wallac Oy Homogen bestaemningsmetod som utnyttjar affinitetsreaktioner
US5547669A (en) * 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
FI88654C (fi) * 1991-03-15 1993-06-10 Datacity Center Oy Fluorescenshoejningsmetod
US5200318A (en) * 1992-05-13 1993-04-06 Miles Inc. Diagnosis of IDDM with a panel of immunoreagents
DE4233353A1 (de) * 1992-10-05 1994-04-07 Wella Ag Haarkurmittel
US5989551A (en) * 1995-10-25 1999-11-23 The United States Of America As Represented By The Department Of Health And Human Services Materials and methods for detection and treatment of insulin-dependent diabetes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674692A (en) * 1991-09-06 1997-10-07 Baekkeskov; Steinunn Methods for diabetes susceptibility assessment in asymptomatic patients
WO1997032984A1 (fr) * 1996-03-06 1997-09-12 Zymogenetics, Inc. PROTEINE-TYROSINE PHOSPHATASE AUTO-ANTIGENE DE 37 kD DU DIABETE SUCRE
WO1999032136A1 (fr) * 1997-12-23 1999-07-01 Alexion Pharmaceuticals, Inc. Proteines chimeres pour le traitement du diabete

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HEMMILÄ I ET AL: "Europium as a label in time-resolved immunofluorometric assays", ANALYTICAL BIOCHEMISTRY, ORLANDO, FL, US, vol. 137, no. 2, March 1984 (1984-03-01), pages 335 - 343, XP002121696, ISSN: 0003-2697 *
HONEYMAN ET AL.: "High T cell responses to the glutamic acid decarboxylase (GAD) isoform 67 reflect a hyperimmune state that preceedes the onset of insulin-dependent diabetes", JOURNAL OF AUTOIMMUNITY, vol. 10, 1997, pages 165 - 173, XP002203972 *
MEHTA H B ET AL: "DELISA: sensitive nonisotopic assay for GAD65 autoantibodies, a key risk-assessment marker for insulin-dependent diabetes mellitus", CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY. WINSTON, US, vol. 42, no. 2, 1996, pages 263 - 269, XP002118748, ISSN: 0009-9147 *
PAPOUCHADO M L ET AL: "Highly-sensitive and specific enzyme-linked immunosorbent assays for GAD65 autoantibodies using a thioredoxin-GAD65 fusion antigen", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 207, no. 2, 24 September 1997 (1997-09-24), pages 169 - 178, XP004126301, ISSN: 0022-1759 *

Also Published As

Publication number Publication date
EP0940470A2 (fr) 1999-09-08
US6770460B1 (en) 2004-08-03

Similar Documents

Publication Publication Date Title
EP0940470A3 (fr) Protéine de fusion et sa utilisation pour la détection des anticorps liée au diabète mellitus insulinodépendant
CA2019559A1 (fr) Recepteurs bispecifiques et oligospecifiques mono- et oligovalents, preparation et utilisation
EP1526141A3 (fr) complexes majeurs d'histocompatibilite et leurs utilisations
WO1998050547A3 (fr) Recepteur proteique humain du type toll, reactifs connexes et techniques afferentes
CA2348379A1 (fr) Dosage immunologique du peptide c humain et trousse pour ces dosages
EP2172486A3 (fr) Anticorps monoclonal contre un prion et son utilisation pour la détection de prions
WO2002099119A3 (fr) Acides nucleiques et polypeptides associes a b7 utiles pour l'immunomodulation
WO2001094413A3 (fr) Acides nucleiques et polypeptides apparentes a b7 utiles pour effectuer une immunomodulation
WO2004083234A3 (fr) Conjugues polypeptide insulinique-oligomere, conjugues polypeptide proinsulinique-oligomere, et procedes de synthese correspondants
CA2056279A1 (fr) Essais de liaison de recepteur acellulaire, leur production et leur utilisation
WO1999003987A3 (fr) Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
CA2010275A1 (fr) Antigenes de cellules des ilots pancreatiques obtenus par clonage moleculaire
EP0840126A3 (fr) Marqueur et réactif immunologique pour l'amyloidose relative à une dialyse, le diabète sucré et les complications du diabète sucré
Kato et al. Enzyme-linked Immunoassay: II. A Simple Method for Synthesis of the Rabbit Antibody-(β-D-Galactosidase Complex and Its General Applicability
MY127575A (en) Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
CA2224404A1 (fr) Kinase h-sgk humaine regulee par le volume cellulaire
WO2005033267A3 (fr) Antigenes cibles par des lymphocytes t pathogenes predominant dans le diabete type 1 et utilisations correspondantes
ZA200006309B (en) A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof.
EP0453097A3 (fr) Composition comprenant au moins deux anticorps differents ou leurs fragments
WO2000061747A3 (fr) Proteines transmembranaires clasp-2
EP1892251A3 (fr) Acides nucléiques et polypeptides apparentés à B7 utiles pour effectuer une immunomodulation
WO2001000799A8 (fr) Nouvelle proteine et son adn
EP1702984A3 (fr) Méthode pour la détection du cancer de la prostate
WO1998001462A3 (fr) Peptides du complexe tlp isole du carcinome de l'appareil genital et anticorps contre lesdits peptides
EP1149914A3 (fr) Proteine fusionnèe qui reconnaít les auto-anticorps humain simultanement

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17P Request for examination filed

Effective date: 20021223

AKX Designation fees paid

Designated state(s): BE DE DK FI FR GB IT NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071221